Sideroblastic anemia in multiple myeloma: a preleukemic change.
D000756:Anemia, Sideroblastic / Q000139:chemically induced*; D001856:Bone Marrow Examination; D003561:Cytarabine / Q000627:therapeutic use; D005260:Female; D006801:Humans; D005779:Immunodiffusion; D007122:Immunoelectrophoresis; D007136:Immunoglobulins / Q000032:analysis; D007501:Iron / Q000097:blood; D007948:Leukemia, Monocytic, Acute / Q000150:complications; D015470:Leukemia, Myeloid, Acute / Q000150:complications / Q000188:drug therapy; D008297:Male; D008558:Melphalan / Q000627:therapeutic use; D015122:Mercaptopurine / Q000627:therapeutic use; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications* / Q000188:drug therapy; D009113:Muramidase / Q000097:blood; D011230:Precancerous Conditions; D011241:Prednisone / Q000627:therapeutic use; D013194:Staining and Labeling; D014750:Vincristine / Q000627:therapeutic use
D007136:Immunoglobulins; D003561:Cytarabine; D014750:Vincristine; D007501:Iron; D015122:Mercaptopurine; D009113:Muramidase; D008558:Melphalan; D011241:Prednisone